In this review, we focus on RKIP and its downstream target, the extracellular signal-regulated kinases 1 and 2 (ERK1/2), two key regulators of cancer and heart disease that can be leveraged as therapeutic targets to treat these diseases while avoiding toxic side effects. This evidence concerns the gene MAPK3 and heart disorder.